Christopher Lowe

Chris Lowe received B.S. degrees in Chemical Engineering and Biochemistry & Molecular Biology from the University of Massachusetts Amherst in 2012. Chris went on to complete his PhD in Biomedical Engineering from Rutgers University in 2018 focused on cell culture, biomaterials, and drug delivery. He was awarded the 2019 Rutgers School of Engineering Outstanding Graduate Student Award for accomplishments in scholarship, teaching, and service.

Chris joined the Biotherapeutics Process Development group at Shire as an upstream process development engineer in 2018. He continued in this role when Shire was acquired by Takeda and has led or contributed to the development, scale-up, and tech transfer of several candidate biologics including complex multi-specifics, antibody drug conjugates, enzyme therapies, and traditional monoclonal antibodies. Chris has also championed the development and implementation of automated tools to 40+ bioreactors throughout Takeda’s process development labs and pilot plant. These tools have reduced the need for hands-on operations, replacing regularly required manual sampling and feeding activities, enabling high frequency data collection and feedback control, and increasing bioreactor throughput within the labs.

Chris has a long history of involvement with AIChE dating back to his time as an undergraduate in the UMass Amherst student chapter and has included service as a volunteer leader with the Executive Student Committee (ESC), Young Professionals Committee (YPC; now Early Career Community ECC), Career and Education Operating Council (CEOC), and Pharmaceutical Development, Discovery, and Manufacturing Forum (PD2M). In 2023 Chris was recognized as one of AIChE’s 35 Under 35 Award winners in the leadership category.